

ACT UP, 268-271, 298

adenylate cyclase, see adenylyl cyclase

adenylyl cyclase

ibogaine potentiation of morphine effect on, 7

ibogaine potentiation of serotonin effect on, 12, 146

mu-opioid inhibition of, 98-99

Adriaans, Nico

Dutch Junkiebond and, 253, 283-284

Dutch Addict Self-Help (DASH) and, 283-4, 298, 302, 311

Erasmus University and, 258-259, 271, 298

view on importance of peer counseling in ibogaine treatment, 290

acetylcholine,

EEG and, 9, 28-29

muscarinic acetylcholine receptors, *iboga* alkaloids and, 9, 41, 50

nicotinic acetylcholine receptors, *iboga* alkaloids and, 6, 9-10, 41, 50-51

REM sleep and, 29

affinity of *iboga* alkaloids at various receptor sites, tables, 41, 81, 167

anomie, 238

anxiety

cocaine withdrawal and, 146-148

ibogaine and, 227-234

kappa-opioid receptors and, 231-232

Bastiaans, Jan, Dr.

ibogaine treatments in the Netherlands, and, 260, 285, 298

LSD and, 260

Beal, Dana (see also Cures-not-Wars), 271-272

benzodiazepine receptor, 179

binding, space and time, *iboga* and, 239, 244

Bin-Wahad, Dhoruba, 272

Bwiti

estimated dosages of *iboga* alkaloids used, table, 242

sacramental use of *iboga*, 30, 235-247, 294

work of the ancestors, *iboga* and, 239, 245

cannabis, market separation from hard drugs, 270

cardiovascular effects, *iboga* alkaloids, 25, 49, 166-167

cerebellar Purkinje cells, climbing fiber synapses originating from the inferior olive, excitotoxicity and, 12, 184-185

charismatic group, 30

Chemical Abstracts ibogamine skeleton numbering, 3, (see *A Note Concerning the Numbering of Iboga Alkaloids*)

Christiana, Copenhagen, 261-263

civil disobedience, 267

Clouet, Doris, Dr., 252-253

Cocaine

cardiovascular effects of ibogaine and 166

dopamine efflux in the rat NAc, *iboga* alkaloids and, 15-16

dopamine efflux in mouse brain slice, ibogaine and effect of kappa-opioid antagonist, 8

EEG effects of ibogaine and, 196-200

locomotor response to, *iboga* alkaloids and, 46-47, 51

self- administration, *iboga* alkaloids and 5, 12-13, 16, 22, 42,45-46, 48, 119, 127-129

sensitization, 15-16, 47-48

stereotypy and, 46-47

withdrawal anxiety, ibogaine and, 146-148

colonialism 30, 237-40

corticosterone secretion

rat, ibogaine and, 200-201

rat, ibogaine and noribogaine and, 100-103

craving, drug

animal model, 220-221

measurement in humans utilizing the Heroin Craving Questionnaire (HCQ-29), 163, 165

effects on with ibogaine in humans, 16-17, 165-169, 284, 287

Cures-not-Wars, 264, 272, 275

cytochrome P450 2D6 (CYP2D6), 82-83, 158-161

Czech Republic, ibogaine scene in, 264-265

DASH (Dutch Addict Self-Help), 253, 257-58

Doors of Perception, The, 251

dopamine

brain tissue levels, effect of ibogaine on, 9, 87-91, 108, 199-202

efflux, NAc, cocaine, *iboga* alkaloids and, 15-16, 47-48

efflux, NAc, morphine, *iboga* alkaloids and, 15, 45

efflux, NAc, nicotine, *iboga* alkaloids and, 15-16, 47-48

receptor affinity, *iboga* alkaloids, 9, 41,

transporter, *iboga* alkaloids and, 9, 86-87, 117

Dole, Vincent P. Dr., 290, 312

DOM (2,5-dimethoxy-4-methylamphetamine), 10, 63, 66-69, 71

Drug discrimination

beta-carbolines in ibogaine-trained animals, 11, 69-71

fixed ratio schedule, 64

NMDA antagonists in ibogaine-trained animals, 11, 72

nonessential stimulus components, ibogaine, 10-11, 66-69

noribogaine in ibogaine-trained animals, 11, 74-75

opioids in ibogaine-trained animals, 73-74

serotonergic agents in ibogaine-trained animals, 8, 10-11, 66-69, 75

sigma ligands in ibogaine-trained animals, 74-75

dynorphin, ibogaine and, 11

ECoG (electrocorticogram) 194-200

EEG (electroencephalogram)

ibogaine and, 9, 24, 28-29

effect of cocaine in rats pretreated with ibogaine 194-200

learning and, 29-30

ethanol self-administration, *iboga* alkaloids and, 12, 51, 127

Erasmus University, Rotterdam, 253-254, 257-259, 271, 298

eye movements, observations reported by treatment guides, 30

fatalities, 25-27

FDA (US Food and Drug Administration)

approval of IND submitted by D. Mash, 5, 255, 303

scheduling of ibogaine, 4

fenfluramine, 8, 66, 92, 102, 201

fluoxetine, 11, 69

fluvoxamine, 69

focus group for participants in DASH treatments, 258, 284

Fluoro-Jade, cerebellar degeneration and, 23, 208

Frenken, Geerte, 257

Gabon 4, 253, 265, 294

GFAP (glial fibrillary acid protein), 22-23, 106, 203-204

gender differences

bioavailability, 19-20, 84

kinetics and metabolism of ibogaine and noribogaine in rats, 84-85, 107-108

neuropathology, 22

visual phenomena related to ibogaine in humans, 256

Glick, Stanley, Dr., 253

glycine, 7, 58-59, 61

Goutarel, Robert, 29-30, 256, 275

guide, treatment, 17, 285-288, 300

hallucinations, 18-19, 286

haloperidol, sigma receptor and, 174, 176

harm reduction, 267-268, 270-272, 278, 290

harmaline 107, 174, 184-185, 188

Harms, Josien 257, 283

heroin

self-administration, ibogaine and, 12-13
smoking, 26
withdrawal, human, ibogaine and 17, 155-172, 284-298,

ibogaine

chemical properties, 2-3
mechanisms of action, 6-10, 40-41, 49-51, 55-62, 115-133, 140-142, 167-169
opioid receptors and, 7-8, 41, 167-169
pharmacokinetics, see pharmacokinetics, ibogaine
possible differences related to manufacturing source, 119
price, Slovenia, 261
scheduling, 4, 250-251, 268, 272

Ibogaine Mailing List 6, 262, 276

Ibogaine Story, The 264, 275

ICASH (International Coalition of Addict Self-Help) 5, 283, 298-299

INTASH (International Addict Self-Help) 235, 239-243, 254, 257, 283, 285-286, 290, 302

Internet, 6, 262, 264, 276-277

Isbell, Harris, Dr., 4

Junkiebond, Dutch, 253, 268, 270-271, 283

Kabouters, 269

Kaplan, Charles, Dr., 258-259, 284

Ka-Tzetnik 135633 (Yehiel De-Nur), 260

Kleber, Herbert, Dr. 284

Lambarène, 4, 115

LeMen and Taylor ibogamine skeleton numbering, 3, (see *A Note Concerning the Numbering of Iboga Alkaloids*)

Lieberman, Dan, 263, 265-266

locomotor activity

cocaine, *iboga* alkaloids, and 14-15, 46-48, 91
morphine, *iboga* alkaloids and, 14-15, 44-45
stereotypy and, 15, 47

long-term outcomes, ibogaine treatments, 17-18, 156

Lotsof, Howard
initial observations of ibogaine effect in humans, 4, 251-252, 294-295
patents for use of ibogaine in drug dependence and, 4-5, 253
NDA International and, 253-254

LSD (lysergic acid diethylamide)
Jan Bastiaans and, 260
5HT_{2A} receptor and, 66-69

Mash, Deborah, Dr.,
FDA and, 5, 166, 254-55
St. Kitts and, 17, 25, 155-171, 255

Memantine, 57, 59, 61

18-Methoxycoronaridine (18-MC)
drug self-administration and, 13, 40-46, 48, 51
locomotor behavior and, 44-48
morphine withdrawal and, 40, 43-44, 47, 51
NMDA receptors and, 41, 44-45, 49, 60-61
opioid receptors and, 41, 44-45, 49, 51
serotonin and, 41, 49, 51
sigma receptors and 41, 49, 79-83

morphine
dopamine efflux in NAc, *iboga* alkaloids and 15, 45
locomotor response to, *iboga* alkaloids and, 14, 44
modulation of effects by ibogaine, 212
self-administration, *iboga* alkaloids and, 42-43, 213-214
withdrawal, animal, effect of *iboga* alkaloids, 13-14, 40, 43-44, 51, 98-99, 215-
219

mouse
differences from the rat regarding ibogaine with regard to ibogaine effect on
locomotor response to cocaine, 15
differences from the rat regarding ibogaine neurotoxic effects, 207-208
knockout, 117, 125, 128
morphine withdrawal and, 14

Naranjo, Claudio, Dr., 4,

NDA International, 15, 251, 253-255, 259-260, 268, 298, 303

NDE (near death experience), 30-31

neurotensin-like immunoreactivity (NTLI), ibogaine and, 11

neurotoxicity

human evidence 24-25

neuropathological studies in animals 22-24, 105-107, 202-209

sigma receptors and, 173-174, 176, 184-186, 188

NIAD (Netherlands Institute for Alcohol and Drugs) 259, 285

nicotine

dopamine efflux, *iboga* alkaloids and, 10, 15-16, 45, 47

self-administration/ preference, *iboga* alkaloids and, 5, 12-13, 33, 42, 46

nicotinic acetylcholine receptor, see acetylcholine

NIDA (National Institute on Drug Abuse), 2, 5 252-254, 259, 267, 269, 271-275, 278

NIDA Ibogaine Review Meeting, March 1995, 5, 17

NIH (National Institutes of Health), 273

NMDA (*N*-methyl-D-aspartate)

affinity of ibogaine for the NMDA receptor 6-7, 41, 56-60, 81, 167

discriminative stimulus of ibogaine, and, 11, 72-73,

effects of NMDA antagonists in opioid withdrawal 59

functional evidence for ibogaine as NMDA antagonist 7, 56-60, 184

18-MC and, 41,44-45, 49, 60-61

noribogaine and 41, 60, 81, 105, 167

sigma receptors and, 174-175, 184-185

norharman, effect on morphine withdrawal, 14

noribogaine (10-hydroxyibogamine)

identification as a primary metabolite of ibogaine, 81-82, 157-158

NMDA receptors and 41, 60, 81, 105, 167

opioid receptors and, 7-8, 41, 81, 108, 167-169

serotonin receptor interactions, 41, 81, 167

serotonin release in NAc and, 47

sigma receptors and, 179-187

tissue dopamine levels and, 108

normalization, 252, 271

nucleus accumbens (NAc)

core vs. shell regions, 12, 15-16

dopamine efflux in response to drugs, effects of *iboga* alkaloids, 15-16, 45, 47-48

olivocerebellar projection, 23, 184-185

oneiric/ oneirophrenic effects, 18, 275, 309

opioid receptors, interactions with *iboga* alkaloids,

ibogaine 8, 41, 167-169

18-MC 41, 44-45, 49, 51

noribogaine 7-8, 41, 81, 108, 167-169

Parker, Jon, 24

panoramic memory, 18, 28, 30, 287-288, 299-301

pharmacokinetics, ibogaine

animal pharmacokinetic studies 19-20, 81-85, 95, 161

gender and gonadectomy and, 84-85

heterogeneity among CYP isoforms, 20, 158-160, 162

humans, 19-20, 159-160

place preference

amphetamine, ibogaine and, 220

morphine, ibogaine and, 220

plus maze, 146-148, 151, 229-232

political theater, tactics of, 269-271

prolactin secretion

rat, effect of ibogaine 200-201

rat, effect of ibogaine and noribogaine 100-103

Provos, 269

reinstatement paradigm, 220

REM sleep 29-30

Resinovic, Marko, 260-261

Rock Against Racism, 272

runway paradigm, rewarding and aversive effects of drugs and, 220-221

Russia, 285, 291

Sandberg, Nick, 264

Sanders, Chris, 264

“Sara”, 263-264

Secret Chief, The, 256

second messenger signal transduction, ibogaine and, 7, 12, 33, 139-140, 142, 145

sensitization, effects of *iboga* alkaloids on neuroadaptations related to, 12, 15-16, 28, 43-48

serotonin

extracellular levels in NAc, *iboga* alkaloids and, 47, 49

inhibition of adenylyl cyclase, enhancement by ibogaine, 12, 146

putative role in ibogaine’s mechanism of action, 108

release, *iboga* alkaloids and, 8, 49, 102

serotonin (5HT) receptors

5HT_{2A} receptor, LSD and, 8, 10, 66-69

affinity, 5HT_{1A} receptor, *iboga* alkaloids, 41

affinity, 5HT_{2A} receptor, *iboga* alkaloids, 8, 41

affinity, 5HT_{2C} receptor, *iboga* alkaloids, 41

affinity, 5HT₃ receptor, *iboga* alkaloids, 8, 41, 51

serotonin transporter (SERT), *iboga* alkaloids and, 6, 8, 49, 81, 84-86, 108, 117, 167-168,

sigma receptors

affinity, ibogaine, 10, 41, 81, 178-180

affinity, 18-MC, 41, 179-181

affinity, noribogaine, 41, 179-180, 185

apoptosis and, 176-178, 181-182

general characteristics and functions 174-176

iboga alkaloids and, 173-192

neuroleptics and, 174-175

putative role in ibogaine neurotoxicity, 23-24, 173-191

sigma₁ receptor 174-180

sigma₂ receptor, calcium signaling and, 177-178

steroids as sigma receptor ligands, 175

tremor and, 186-188

Sisko, Robert, 253, 283

Slovenia, ibogaine scene in, 260-261

sodium channels, ibogaine and 18-MC affinity for, 6, 50

stages of subjective experience in patients treated with ibogaine, 18-19, 286-287, 306-307

substance P, ibogaine and, 11

Taub, Eric, 255-256

tremor

iboga alkaloids and, 24, 40, 48-49, 60, 104-105, 186-188, 214

sigma binding affinity and, 186-188

United Kingdom, ibogaine scene in, 264

Venlafaxine, 69

Vocci, Frank, 5, 275

Waltenburg, Carl, 261-263

withdrawal, opioid, animal, *iboga* alkaloids in, 13-14, 40, 43-44, 51, 98-99, 215-219

withdrawal, opioid, human,

dextromethorphan in, 59

ibogaine in, 4, 16-17, 155-170, 284, 294-295

measurement using OOWS (Objective Opiate Withdrawal Scale) 162-164, 172

Wright, Curtis, 32, 250

Yippies 269-271